Development of asymmetric membrane capsules of metformin hydrochloride for oral osmotic controlled drug delivery
Main Article Content
Abstract
of drugs in a controlled manner. In the present work, we developed a semi‑automatic process by fabricating a hydraulic
assisted mechanical robotic arm for the manufacturing of asymmetric membrane capsules and the process was validated
in comparison with the manual procedure of manufacturing. The capsule walls were made by dip coating phase inversion
process using cellulose acetate butyrate as polymer and propylene glycol as plasticizer/pore forming agent. The comparative examination of physical parameters in manual and semi‑automatic process confirmed the consistency, reproducibility and efficiency of the semi‑automatic process over manual procedure. The resulting asymmetric membrane wall was evaluated by scanning electron microscopy studies revealed the thin dense region supported on a thicker porous region. Fourier
transform infrared studies showed phase inversion of the asymmetric membrane as compared to plain membrane. Osmotic release study and in vitro behavior was studied for controlled delivery of metformin hydrochloride as a model drug. In vitro release studies of the formulations showed that drug release was dependent on the concentration of pore forming agent, level of osmogents and independent of the media pH and agitation. The effect of the process variables on the drug release
was optimized using 23 full factorial design and the release kinetics of the optimized formulation confirmed zero order
kinetics with a controlled drug delivery of 13 h and the mechanism of drug release was found to be super case II transport.
Downloads
Article Details
This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.
References
Jerzeweski RL, Chein YW. Osmotic drug delivery, in treatise on controlled
drug delivery. Fundamentals, Optimization, Applications. 1st ed.
New York: Marcel Dekker; 1987; p. 225‑53.
Verma RK, Krishna DM, Garg S. Formulation aspects in the development
of osmotically controlled oral drug delivery systems. J Control Release
;79:7‑27.
Joseph RR, Lee HL. Controlled Drug Delivery: Fundamentals and
Applications. 2nd ed. New York: Marcel Dekker; 1987; p. 414‑20.
Santus G, Baker RW. Osmotic drug delivery: A review of the patent
literature. J Control Release 1995;35:1‑21.
Pandey S, Viral D. Osmotic pump drug delivery devices: From implant
to sandwiched oral therapeutic system. Int J Pharm Technol Res
;2:693‑9.
Thakur RS, Majumdar JK, Rajput GC. Review: Osmotic delivery systems
current scenario. J Pharm Res 2010;34:771‑5.
Donald L. Hand Book of Pharmaceutical Controlled Release Technology.
nd ed. Philadelphia: Marcell Dekker; 2003; p. 751‑84.
Hermann LS, Melender A. Biguanides: Basic Aspects and Clinical Use.
rd ed. New York: Wiley; 1992. p. 773‑95.
Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, Woods HF. Metformin
kinetics in healthy subjects and in patients with diabetes mellitus. Br J
Clin Pharmacol 1981;12:235‑46.
Thombre AG, Cardinal JR, DeNoto AR, Gibbes DC. Asymmetric membrane
capsules for osmotic drug delivery II. In vitro and in vivo drug release
performance. J Control Release 1999;57:65‑73.
Thombre AG, Cardinal JR, DeNoto AR, Herbig SM, Smith KL. Asymmetric
membrane capsules for osmotic drug delivery. I. Development of a
manufacturing process. J Control Release 1999;57:55‑64.
Thombre AG, DeNoto AR, Gibbes DC. Delivery of glipizide from
asymmetric membrane capsules using encapsulated excipients. J Control
Release 1999;60:333‑41.
Bengt L, Marie S, Johan HJ. Osmotic pumping release form KCl tablets
coated with porous and non‑porous ethylcellulose. Int J Pharm
;67:21‑7.
Bharath S, Rani RH. Formulation and characterization of asymmetric
membrane capsules of cellulose acetate. Int J Chem Sci 2008;6:390‑8.
Herbig SM, Cardinal JR, Korsmeyer RW, Smith KL. Asymmetric‑membrane
tablet coatings for osmotic drug delivery. J Control Release
;35:127‑36.
Wakode R, Amrita B. Once a day osmotic drug delivery system for highly
water soluble pramipexole. J Pharm Chem Res 2010;2:136‑46.
Anish C, Millay J, Ashish M. Fabrication and evaluation of osmotic capsular
pump for controlled drug delivery. Int J Pharm Pharm Sci 2010;2:18‑23.
Philip AK, Pathak K, Shakya P. Asymmetric membrane in membrane
capsules: A means for achieving delayed and osmotic flow of cefadroxil.
Eur J Pharm Biopharm 2008;69:658‑66.
Kumar G, Gupta GD. Development and in vitro evaluation of osmotically
controlled oral drug delivery system of carvedilol. Int J Pharm Sci Drug
Res 2009;1:80‑2.
Higuchi T. Mechanism of sustained‑action medication. Theoretical
analysis of rate of release of solid drugs dispersed in solid matrices.
J Pharm Sci 1963;52:1145‑9.
Hixson AW, Crowell JH. Dependence of reaction velocity upon surface
and agitation. Ind Eng Chem 1931;23:923‑31.
Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute
release from porous hydrophilic polymers. Int J Pharm 1983;15:25‑35.
Lin YK, Ho HO. Investigations on the drug releasing mechanism from an
asymmetric membrane‑coated capsule with an in situ formed delivery
orifice. J Control Release 2003;89:57‑69.
Wang CY, Ho HO, Lin LH, Lin YK, Sheu MT. Asymmetric membrane capsules
for delivery of poorly water‑soluble drugs by osmotic effects. Int J Pharm
;297:89‑97.
Choudhury PK, Ranawat MS, Pillai MK, Chauhan CS. Asymmetric
membrane capsule for osmotic delivery of flurbiprofen. Acta Pharm
;57:343‑50.
Wang GM, Chen CH, Ho HO, Wang SS, Sheu MT. Novel design of osmotic
chitosan capsules characterized by asymmetric membrane structure for
in situ formation of delivery orifice. Int J Pharm 2006;319:71‑81.
Grimm W. Extension of the international conference on harmonization
tripartite guideline for stability testing of new drug substances and
products to countries of climatic zones III and IV. Drug Dev Ind Pharm
;24:313‑25.